Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Nov;24(58):1–96. doi: 10.3310/hta24580

Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.

Richard E Appleton, Naomi Ea Rainford, Carrol Gamble, Shrouk Messahel, Amy Humphreys, Helen Hickey, Kerry Woolfall, Louise Roper, Joanne Noblet, Elizabeth Lee, Sarah Potter, Paul Tate, Nadia Al Najjar, Anand Iyer, Vicki Evans, Mark D Lyttle
PMCID: PMC7701993  PMID: 33190679

Abstract

BACKGROUND

Convulsive status epilepticus is the most common neurological emergency in children. Its management is important to avoid or minimise neurological morbidity and death. The current first-choice second-line drug is phenytoin (Epanutin, Pfizer Inc., New York, NY, USA), for which there is no robust scientific evidence.

OBJECTIVE

To determine whether phenytoin or levetiracetam (Keppra, UCB Pharma, Brussels, Belgium) is the more clinically effective intravenous second-line treatment of paediatric convulsive status epilepticus and to help better inform its management.

DESIGN

A multicentre parallel-group randomised open-label superiority trial with a nested mixed-method study to assess recruitment and research without prior consent.

SETTING

Participants were recruited from 30 paediatric emergency departments in the UK.

PARTICIPANTS

Participants aged 6 months to 17 years 11 months, who were presenting with convulsive status epilepticus and were failing to respond to first-line treatment.

INTERVENTIONS

Intravenous levetiracetam (40 mg/kg) or intravenous phenytoin (20 mg/kg).

MAIN OUTCOME MEASURES

Primary outcome - time from randomisation to cessation of all visible signs of convulsive status epilepticus. Secondary outcomes - further anticonvulsants to manage the convulsive status epilepticus after the initial agent, the need for rapid sequence induction owing to ongoing convulsive status epilepticus, admission to critical care and serious adverse reactions.

RESULTS

Between 17 July 2015 and 7 April 2018, 286 participants were randomised, treated and consented. A total of 152 participants were allocated to receive levetiracetam and 134 participants to receive phenytoin. Convulsive status epilepticus was terminated in 106 (70%) participants who were allocated to levetiracetam and 86 (64%) participants who were allocated to phenytoin. Median time from randomisation to convulsive status epilepticus cessation was 35 (interquartile range 20-not assessable) minutes in the levetiracetam group and 45 (interquartile range 24-not assessable) minutes in the phenytoin group (hazard ratio 1.20, 95% confidence interval 0.91 to 1.60; p = 0.2). Results were robust to prespecified sensitivity analyses, including time from treatment commencement to convulsive status epilepticus termination and competing risks. One phenytoin-treated participant experienced serious adverse reactions.

LIMITATIONS

First, this was an open-label trial. A blinded design was considered too complex, in part because of the markedly different infusion rates of the two drugs. Second, there was subjectivity in the assessment of 'cessation of all signs of continuous, rhythmic clonic activity' as the primary outcome, rather than fixed time points to assess convulsive status epilepticus termination. However, site training included simulated demonstration of seizure cessation. Third, the time point of randomisation resulted in convulsive status epilepticus termination prior to administration of trial treatment in some cases. This affected both treatment arms equally and had been prespecified at the design stage. Last, safety measures were a secondary outcome, but the trial was not powered to demonstrate difference in serious adverse reactions between treatment groups.

CONCLUSIONS

Levetiracetam was not statistically superior to phenytoin in convulsive status epilepticus termination rate, time taken to terminate convulsive status epilepticus or frequency of serious adverse reactions. The results suggest that it may be an alternative to phenytoin in the second-line management of paediatric convulsive status epilepticus. Simple trial design, bespoke site training and effective leadership were found to facilitate practitioner commitment to the trial and its success. We provide a framework to optimise recruitment discussions in paediatric emergency medicine trials.

FUTURE WORK

Future work should include a meta-analysis of published studies and the possible sequential use of levetiracetam and phenytoin or sodium valproate in the second-line treatment of paediatric convulsive status epilepticus.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN22567894 and European Clinical Trials Database EudraCT number 2014-002188-13.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 58. See the NIHR Journals Library website for further project information.

Plain language summary

Most epileptic tonic–clonic seizures, also called convulsions, last for < 4 minutes and stop spontaneously. A convulsion that lasts for > 5 minutes is called convulsive status epilepticus. This may cause neurological abnormalities or, rarely, death. There is good scientific evidence for the best first-line medicine, called a benzodiazepine, to stop convulsive status epilepticus. When a benzodiazepine has not stopped status, a second-line medicine is given. The usual second-line medicine, which has been used for > 50 years, is phenytoin (Epanutin, Pfizer Inc., New York, NY, USA). However, it stops status in only half of children. It must be given slowly because it can cause unpleasant and potentially serious side effects. A new medicine called levetiracetam (Keppra, UCB Pharma, Brussels, Belgium) may be more effective. It seems to have less serious side effects than phenytoin. However, there is no good scientific evidence as to whether phenytoin or levetiracetam is better. A randomised controlled trial is the best scientific way to decide which of these two medicines is better. The Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) trial was a randomised controlled trial that compared levetiracetam with phenytoin. A total of 152 children were randomised to receive levetiracetam and a total of 134 children were randomised to receive phenytoin. Research without prior consent was shown to be acceptable to parents, doctors and nurses. Parents’ consent to use their child’s data and continue in the trial was provided after the emergency situation was resolved. Convulsive status epilepticus stopped in 70.4% of the levetiracetam-treated children and in 64% of the phenytoin-treated children. The median time to status stopping was 35 minutes in the levetiracetam-treated children and 45 minutes in the phenytoin-treated children. Only one participant on phenytoin (vs. none on levetiracetam) experienced serious side effects that were thought to be caused by their treatment. None of the results showed any statistically significant or meaningful difference between levetiracetam and phenytoin. However, the results suggest that levetiracetam might be an alternative choice to phenytoin.

Full text of this article can be found in Bookshelf.

References

  1. Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393:2125–34. https://doi.org/10.1016/S0140-6736(19)30724-X doi: 10.1016/S0140-6736(19)30724-X. [DOI] [PMC free article] [PubMed]
  2. Lyttle MD, Gamble C, Messahel S, Hickey H, Iyer A, Woolfall K, et al. Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial. Trials 2017;18:283. https://doi.org/10.1186/s13063-017-2010-8 doi: 10.1186/s13063-017-2010-8. [DOI] [PMC free article] [PubMed]
  3. ISRCTN registry. Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus. URL: www.isrctn.com/ISRCTN22567894 (accessed 24 September 2020).
  4. Novorol CL, Chin RF, Scott RC. Outcome of convulsive status epilepticus: a review. Arch Dis Child 2007;92:948–51. https://doi.org/10.1136/adc.2006.107516 doi: 10.1136/adc.2006.107516. [DOI] [PMC free article] [PubMed]
  5. Chin RF, Neville BG, Peckham C, Bedford H, Wade A, Scott RC, NLSTEPSS Collaborative Group. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006;368:222–9. https://doi.org/10.1016/S0140-6736(06)69043-0 doi: 10.1016/S0140-6736(06)69043-0. [DOI] [PubMed]
  6. PICANet. Annual Report 2010. URL: www.picanet.org.uk/wp-content/uploads/sites/25/2018/05/PICANet_Annual_Report_2010-1.pdf (accessed 18 October 2020).
  7. Metsäranta P, Koivikko M, Peltola J, Eriksson K. Outcome after prolonged convulsive seizures in 186 children: low morbidity, no mortality. Dev Med Child Neurol 2004;46:4–8. https://doi.org/10.1017/s0012162204000027 doi: 10.1017/s0012162204000027. [DOI] [PubMed]
  8. Chin RF, Verhulst L, Neville BG, Peters MJ, Scott RC. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry 2004;75:1584–8. https://doi.org/10.1136/jnnp.2003.032797 doi: 10.1136/jnnp.2003.032797. [DOI] [PMC free article] [PubMed]
  9. Hussain N, Appleton R, Thorburn K. Aetiology, course and outcome of children admitted to paediatric intensive care with convulsive status epilepticus: a retrospective 5-year review. Seizure 2007;16:305–12. https://doi.org/10.1016/j.seizure.2007.01.007 doi: 10.1016/j.seizure.2007.01.007. [DOI] [PubMed]
  10. Eriksson K, Metsäranta P, Huhtala H, Auvinen A, Kuusela AL, Koivikko M. Treatment delay and the risk of prolonged status epilepticus. Neurology 2005;65:1316–18. https://doi.org/10.1212/01.wnl.0000180959.31355.92 doi: 10.1212/01.wnl.0000180959.31355.92. [DOI] [PubMed]
  11. Advanced Life Support Group. A Practical Approach to Emergencies (APLS) 6th Edition. URL: www.alsg.org/home/mod/data/view.php?d=12%26rid=143 (accessed 30 October 2019).
  12. McTague A, Martland T, Appleton R. Drug management for acute tonic–clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2018;1:CD001905. https://doi.org/10.1002/14651858.CD001905.pub3 doi: 10.1002/14651858.CD001905.pub3. [DOI] [PMC free article] [PubMed]
  13. Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav 2016;64:110–15. https://doi.org/10.1016/j.yebeh.2016.09.030 doi: 10.1016/j.yebeh.2016.09.030. [DOI] [PubMed]
  14. Lewena S, Pennington V, Acworth J, Thornton S, Ngo P, McIntyre S, et al. Emergency management of pediatric convulsive status epilepticus: a multicenter study of 542 patients. Pediatr Emerg Care 2009;25:83–7. https://doi.org/10.1097/PEC.0b013e318196ea6e doi: 10.1097/PEC.0b013e318196ea6e. [DOI] [PubMed]
  15. Appleton RE, Gill A. Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure 2003;12:369–72. https://doi.org/10.1016/S1059-1311(02)00338-2 doi: 10.1016/S1059-1311(02)00338-2. [DOI] [PubMed]
  16. Craig S. Phenytoin poisoning. Neurocrit Care 2005;3:161–70. https://doi.org/10.1385/NCC:3:2:161 doi: 10.1385/NCC:3:2:161. [DOI] [PubMed]
  17. Gallop K. Review article: phenytoin use and efficacy in the ED. Emerg Med Australas 2010;22:108–18. https://doi.org/10.1111/j.1742-6723.2010.01269.x doi: 10.1111/j.1742-6723.2010.01269.x. [DOI] [PubMed]
  18. NHS Improvement. Risk of Death and Severe Harm From Error With Injectable Phenytoin. URL: https://improvement.nhs.uk/news-alerts/risk-death-and-severe-harm-error-injectable-phenytoin/ (accessed 30 October 2019).
  19. Berning S, Boesebeck F, van Baalen A, Kellinghaus C. Intravenous levetiracetam as treatment for status epilepticus. J Neurol 2009;256:1634–42. https://doi.org/10.1007/s00415-009-5166-7 doi: 10.1007/s00415-009-5166-7. [DOI] [PubMed]
  20. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord 2009;2:79–91. https://doi.org/10.1177/1756285608100460 doi: 10.1177/1756285608100460. [DOI] [PMC free article] [PubMed]
  21. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008;79:588–9. https://doi.org/10.1136/jnnp.2007.130260 doi: 10.1136/jnnp.2007.130260. [DOI] [PubMed]
  22. Michaelides C, Thibert RL, Shapiro MJ, Kinirons P, John T, Manchharam D, Thiele EA. Tolerability and dosing experience of intravenous levetiracetam in children and infants. Epilepsy Res 2008;81:143–7. https://doi.org/10.1016/j.eplepsyres.2008.05.004 doi: 10.1016/j.eplepsyres.2008.05.004. [DOI] [PubMed]
  23. Rüegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008;12:477–80. https://doi.org/10.1016/j.yebeh.2008.01.004 doi: 10.1016/j.yebeh.2008.01.004. [DOI] [PubMed]
  24. Wheless JW, Clarke D, Hovinga CA, Ellis M, Durmeier M, McGregor A, Perkins F. Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. J Child Neurol 2009;24:946–51. https://doi.org/10.1177/0883073808331351 doi: 10.1177/0883073808331351. [DOI] [PubMed]
  25. Kirmani BF, Crisp ED, Kayani S, Rajab H. Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol 2009;41:37–9. https://doi.org/10.1016/j.pediatrneurol.2009.02.016 doi: 10.1016/j.pediatrneurol.2009.02.016. [DOI] [PubMed]
  26. McTague A, Kneen R, Kumar R, Spinty S, Appleton R. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children’s hospital. Seizure 2012;21:529–34. https://doi.org/10.1016/j.seizure.2012.05.010 doi: 10.1016/j.seizure.2012.05.010. [DOI] [PubMed]
  27. Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2005;4:CD003723. https://doi.org/10.1002/14651858.CD003723.pub2 doi: 10.1002/14651858.CD003723.pub2. [DOI] [PubMed]
  28. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol 2012;259:645–8. https://doi.org/10.1007/s00415-011-6227-2 doi: 10.1007/s00415-011-6227-2. [DOI] [PubMed]
  29. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure 2012;21:233–6. https://doi.org/10.1016/j.seizure.2012.01.008 doi: 10.1016/j.seizure.2012.01.008. [DOI] [PubMed]
  30. Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci 2015;22:959–63. https://doi.org/10.1016/j.jocn.2014.12.013 doi: 10.1016/j.jocn.2014.12.013. [DOI] [PubMed]
  31. Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam – pilot study. Epilepsy Res 2015;114:52–8. https://doi.org/10.1016/j.eplepsyres.2015.04.013 doi: 10.1016/j.eplepsyres.2015.04.013. [DOI] [PubMed]
  32. Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 2013;4:192. https://doi.org/10.3389/fneur.2013.00192 doi: 10.3389/fneur.2013.00192. [DOI] [PMC free article] [PubMed]
  33. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006;47:1128–35. https://doi.org/10.1111/j.1528-1167.2006.00586.x doi: 10.1111/j.1528-1167.2006.00586.x. [DOI] [PubMed]
  34. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010;12:165–72. https://doi.org/10.1007/s12028-009-9304-y doi: 10.1007/s12028-009-9304-y. [DOI] [PubMed]
  35. Hirsch LJ. Levitating levetiracetam’s status for status epilepticus. Epilepsy Curr 2008;8:125–6. https://doi.org/10.1111/j.1535-7511.2008.00266.x doi: 10.1111/j.1535-7511.2008.00266.x. [DOI] [PMC free article] [PubMed]
  36. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 2014;23:167–74. https://doi.org/10.1016/j.seizure.2013.12.007 doi: 10.1016/j.seizure.2013.12.007. [DOI] [PubMed]
  37. Lyttle MD, O’Sullivan R, Hartshorn S, Bevan C, Cleugh F, Maconochie I, PERUKI. Pediatric Emergency Research in the UK and Ireland (PERUKI): developing a collaborative for multicentre research. Arch Dis Child 2014;99:602–3. https://doi.org/10.1136/archdischild-2013-304998 doi: 10.1136/archdischild-2013-304998. [DOI] [PubMed]
  38. Hartshorn S, O’Sullivan R, Maconochie IK, Bevan C, Cleugh F, Lyttle MD, Paediatric Emergency Research in the UK and Ireland (PERUKI). Establishing the research priorities of paediatric emergency medicine clinicians in the UK and Ireland. Emerg Med J 2015;32:864–8. https://doi.org/10.1136/emermed-2014-204484 doi: 10.1136/emermed-2014-204484. [DOI] [PubMed]
  39. National Institute for Health and Care Excellence. Epilepsies: Diagnosis and Management. URL: www.nice.org.uk/guidance/cg137 (accessed 30 October 2019). [PubMed]
  40. Dalziel SR, Furyk J, Bonisch M, Oakley E, Borland M, Neutze J, et al. A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) – a PREDICT study. BMC Pediatr 2017;17:152. https://doi.org/10.1186/s12887-017-0887-8 doi: 10.1186/s12887-017-0887-8. [DOI] [PMC free article] [PubMed]
  41. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019;393:2135–45. https://doi.org/10.1016/S0140-6736(19)30722-6 doi: 10.1016/S0140-6736(19)30722-6. [DOI] [PubMed]
  42. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, et al. The established status epilepticus trial 2013. Epilepsia 2013;54(Suppl. 6):89–92. https://doi.org/10.1111/epi.12288 doi: 10.1111/epi.12288. [DOI] [PMC free article] [PubMed]
  43. Woolfall K, Young B, Frith L, Appleton R, Iyer A, Messahel S, et al. Doing challenging research studies in a patient-centred way: a qualitative study to inform a randomised controlled trial in the paediatric emergency care setting. BMJ Open 2014;4:e005045. https://doi.org/10.1136/bmjopen-2014-005045 doi: 10.1136/bmjopen-2014-005045. [DOI] [PMC free article] [PubMed]
  44. Woolfall K, Roper L, Humphreys A, Lyttle MD, Messahel S, Lee E, et al. Enhancing practitioners’ confidence in recruitment and consent in the EcLiPSE trial: a mixed-method evaluation of site training – a Paediatric Emergency Research in the United Kingdom and Ireland (PERUKI) study. Trials 2019;20:181. https://doi.org/10.1186/s13063-019-3273-z doi: 10.1186/s13063-019-3273-z. [DOI] [PMC free article] [PubMed]
  45. Piper JD, Hawcutt DB, Verghese GK, Spinty S, Newland P, Appleton R. Phenytoin dosing and serum concentrations in paediatric patients requiring 20 mg/kg intravenous loading. Arch Dis Child 2014;99:585–6. https://doi.org/10.1136/archdischild-2013-305093 doi: 10.1136/archdischild-2013-305093. [DOI] [PubMed]
  46. Woolfall K, Gamble C, Frith L, Young B, the CONNECT Advisory Group. Research Without Prior Consent (Deferred Consent) in Trials Investigating the Emergency Treatment of Critically Ill Children: CONNECT Study Guidance Version 2.0. URL: www.liverpool.ac.uk/psychology-health-and-society/research/connect/ (accessed 14 December 2018).
  47. Woolfall K, Frith L, Gamble C, Gilbert R, Mok Q, Young B, CONNECT Advisory Group. How parents and practitioners experience research without prior consent (deferred consent) for emergency research involving children with life threatening conditions: a mixed method study. BMJ Open 2015;5:e008522. https://doi.org/10.1136/bmjopen-2015-008522 doi: 10.1136/bmjopen-2015-008522. [DOI] [PMC free article] [PubMed]
  48. Woolfall K, Frith L, Dawson A, Gamble C, Lyttle MD, the CONNECT Advisory Group, et al. 15 minute consultation: an evidence-based approach to research without prior consent (deferred consent) in neonatal and paediatric critical care trials. Arch Dis Child Educ Pract Ed 2015;101:49–53. https://doi.org/10.1136/archdischild-2015-309245 doi: 10.1136/archdischild-2015-309245. [DOI] [PMC free article] [PubMed]
  49. Woolfall K, Frith L, Dawson A, Gamble C, the CONNECT Advisory Group, Young B. Research Without Prior Consent (Deferred Consent) in Trials Investigating the Emergency Treatment of Critically Ill Children: CONNECT Study Guidance. Liverpool: University of Liverpool; 2015.
  50. Cresswell JW, Plano Clark VL. Designing and Conducting Mixed Methods Research. London: SAGE Publications Ltd; 2007.
  51. Johnstone PL. Mixed methods, mixed methodology health services research in practice. Qual Health Res 2004;14:259–71. https://doi.org/10.1177/1049732303260610 doi: 10.1177/1049732303260610. [DOI] [PubMed]
  52. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 2014;89:1245–51. https://doi.org/10.1097/ACM.0000000000000388 doi: 10.1097/ACM.0000000000000388. [DOI] [PubMed]
  53. Strauss A, Corbin J. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 2nd edn. Thousand Oaks, CA: SAGE Publications Ltd; 1998.
  54. Glaser B. The constant comparative method of qualitative analysis. Soc Probl 1965;12:436–45. https://doi.org/10.2307/798843 doi: 10.2307/798843. [DOI]
  55. Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant 2018;52:1893–907. https://doi.org/10.1007/s11135-017-0574-8 doi: 10.1007/s11135-017-0574-8. [DOI] [PMC free article] [PubMed]
  56. Inwald DP, Canter R, Woolfall K, Mouncy P, Zenasni Z, O’Hara C, et al. Restricted fluid bolus volume in early septic shock: results of the Fluids in Shock pilot trial. Arch Dis Child 2019;104:426–31. https://doi.org/10.1136/archdischild-2018-314924 doi: 10.1136/archdischild-2018-314924. [DOI] [PMC free article] [PubMed]
  57. Realpe A, Adams A, Wall P, Griffin D, Donovan JL. A new simple six-step model to promote recruitment to RCTs was developed and successfully implemented. J Clin Epidemiol 2016;76:166–74. https://doi.org/10.1016/j.jclinepi.2016.02.002 doi: 10.1016/j.jclinepi.2016.02.002. [DOI] [PMC free article] [PubMed]
  58. Shilling V, Williamson PR, Hickey H, Sowden E, Beresford MW, Smyth RL, et al. Communication about children’s clinical trials as observed and experienced: qualitative study of parents and practitioners. PLOS ONE 2011;6:e21604 https://doi.org/10.1371/journal.pone.0021604 doi: 10.1371/journal.pone.0021604. [DOI] [PMC free article] [PubMed]
  59. Behrendt C, Gölz T, Roesler C, Bertz H, Wünsch A. What do our patients understand about their trial participation? Assessing patients’ understanding of their informed consent consultation about randomised clinical trials. J Med Ethics 2011;37:74–80. https://doi.org/10.1136/jme.2010.035485 doi: 10.1136/jme.2010.035485. [DOI] [PubMed]
  60. Featherstone K, Donovan JL. ‘Why don’t they just tell me straight, why allocate it?’ The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med 2002;55:709–19. https://doi.org/10.1016/s0277-9536(01)00197-6 doi: 10.1016/s0277-9536(01)00197-6. [DOI] [PubMed]
  61. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987;17:20–4. https://doi.org/10.2307/3562038 doi: 10.2307/3562038. [DOI] [PubMed]
  62. Fallowfield L, Langridge C, Jenkins V. Communication skills training for breast cancer teams talking about trials. Breast 2014;23:193–7. https://doi.org/10.1016/j.breast.2013.11.009 doi: 10.1016/j.breast.2013.11.009. [DOI] [PubMed]
  63. Jenkins V, Fallowfield L, Solis-Trapala I, Langridge C, Farewell V. Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme. BMJ 2005;330:400. https://doi.org/10.1136/bmj.38366.562685.8F doi: 10.1136/bmj.38366.562685.8F. [DOI] [PMC free article] [PubMed]
  64. Reay H, Arulkumaran N, Brett SJ. Priorities for future intensive care research in the UK: results of a James Lind Alliance priority setting partnership. J Intensive Care Soc 2014;15:288–96. https://doi.org/10.1177/175114371401500405 doi: 10.1177/175114371401500405. [DOI]
  65. Petit-Zeman S, Firkins L, Scadding JW. The James Lind Alliance: tackling research mismatches. Lancet 2010;376:667–9. https://doi.org/10.1016/S0140-6736(10)60712-X doi: 10.1016/S0140-6736(10)60712-X. [DOI] [PubMed]
  66. Peters MJ, Woolfall K, Khan I, Deja E, Mouncey PR, Wulff J, et al. Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial. Crit Care 2019;23:69. https://doi.org/10.1186/s13054-019-2354-4 doi: 10.1186/s13054-019-2354-4. [DOI] [PMC free article] [PubMed]
  67. Wade J, Donovan JL, Athene Lane J, Neal DE, Hamdy FC. It’s not just what you say, it’s also how you say it: opening the ‘black box’ of informed consent appointments in randomised controlled trials. Soc Sci Med 2009;68:2018–28. https://doi.org/10.1016/j.socscimed.2009.02.023 doi: 10.1016/j.socscimed.2009.02.023. [DOI] [PubMed]
  68. Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA. Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol 2011;64:1127–36. https://doi.org/10.1016/j.jclinepi.2010.12.017 doi: 10.1016/j.jclinepi.2010.12.017. [DOI] [PMC free article] [PubMed]
  69. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19:349–57. https://doi.org/10.1093/intqhc/mzm042 doi: 10.1093/intqhc/mzm042. [DOI] [PubMed]
  70. Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019;381:2103–13. https://doi.org/10.1056/NEJMoa1905795 doi: 10.1056/NEJMoa1905795. [DOI] [PMC free article] [PubMed]
  71. Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020;395:1217–24. https://doi.org/10.1016/S0140-6736(20)30611-5 doi: 10.1016/S0140-6736(20)30611-5. [DOI] [PMC free article] [PubMed]
  72. Singh K, Aggarwal A, Faridi MMA, Sharma S. IV Levetiracetam versus IV phenytoin in childhood seizures: a randomized controlled trial. J Pediatr Neurosci 2018;13:158–64. https://doi.org/10.4103/jpn.JPN_126_17 doi: 10.4103/jpn.JPN_126_17. [DOI] [PMC free article] [PubMed]
  73. Nakamura K, Inokuchi R, Daidoji H, Naraba H, Sonoo T, Hashimoto H, et al. Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. Medicine 2017;96:e7206. https://doi.org/10.1097/MD.0000000000007206 doi: 10.1097/MD.0000000000007206. [DOI] [PMC free article] [PubMed]
  74. Senthilkumar CS, Selvakumar P, Kowsik M. Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children. Int J Pediatr Res 2018;5:237–42. https://doi.org/10.17511/ijpr.2018.i04.13 doi: 10.17511/ijpr.2018.i04.13. [DOI]
  75. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005;366:205–10. https://doi.org/10.1016/S0140-6736(05)66909-7 doi: 10.1016/S0140-6736(05)66909-7. [DOI] [PubMed]

RESOURCES